Benefits of CBD liquid for epilepsy may fade with time: study

December 3, 2018 by Dennis Thompson, Healthday Reporter

(HealthDay)—A marijuana-derived drug that helps control epileptic seizures appears to become less effective over time in some patients, a new Israeli study reports.

Cannabidiol (CBD) liquid has been proven effective against seizures, but about one-third of patients develop tolerance that blunts the drug's effectiveness, according to research presented Sunday at the American Epilepsy Society's annual meeting, in New Orleans.

The study was led by Dr. Shimrit Uliel-Sibony, head of the pediatric epilepsy service at Tel Aviv Sourasky Medical Center's Dana-Dwek Children's Hospital in Israel.

Cannabidiol became available in the U.S. market early in November, under the name brand Epidiolex. The U.S. Food and Drug Administration approved Epidiolex for treatment of two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.

Epidiolex, a twice-daily oral solution, is the first FDA-approved drug to contain an ingredient derived from the marijuana plant. CBD does not produce a high; that's caused by another compound in pot called THC.

To see how well CBD works in treating epilepsy, researchers recruited 92 children and adults whose seizures were not responding to other medications. All had used CBD for an average of nearly 20 months.

In this new study, CBD was used in a broader pool of patients, ranging from those with Lennox-Gastaut and Dravet to people with epilepsy caused by stroke.

About 57 percent saw their monthly seizure frequency cut in half while taking CBD, indicating that the treatment is effective.

But tolerance developed in about one-third of those patients after an average of seven months. Doctors needed to increase the dose by 30 percent to get the same benefit; otherwise, the seizures increased by more than 30 percent on the same dose, the findings showed.

Doctors increased the dose of CBD for all patients who developed tolerance, and 12 people responded well while 15 did not.

About one-third of patients stopped taking CBD due to lack of effectiveness or because of side effects, which included sleepiness and gastrointestinal issues, such as nausea, decreased appetite and vomiting, the researchers reported.

These results indicate that CBD is a valuable new epilepsy drug, but is not a magic bullet for treating seizures, epilepsy experts said.

"We often talk about a honeymoon period when patients start a new medication. Many of those patients then relapse," said Dr. Fred Lado, Northwell Health's regional director of epilepsy for Queens and Long Island in New York. "In this study, tolerance decreased after about seven months, which is similar to the honeymoon period we see with other medications."

Dr. Shlomo Shinnar, president of the American Epilepsy Society, agreed that epilepsy drugs tend to lose some effectiveness in patients over time.

"This is not really a big shock: All the drugs we have and use, even when they work, a year later we're frequently moving on to the next drug," said Shinnar, director of the Comprehensive Epilepsy Management Center at the Montefiore Medical Center and the Albert Einstein College of Medicine in New York City.

"This study should temper one's enthusiasm but it should not eliminate one's enthusiasm," he added. "It's still a good drug. I intend to be using it in my ."

There was hope that CBD might have been different from other epilepsy drugs, since the substance promotes increased activity in in the brain, said Dr. Ruben Kuzniecky, director of research and clinical trials at Lenox Hill Hospital in New York City.

Given that, it would have made sense that increases in tolerance would have been limited, he noted.

"This is an important observation given the long-term data," Kuzniecky said. "CBD is a welcome addition to the treatment of certain forms of , but long-term use and larger populations will be needed to understand its limitations."

Research presented at meetings is typically considered preliminary until it is published in a peer-reviewed journal.

Explore further: First U.S. drug containing marijuana-derived ingredient goes on sale

More information: The U.S. Food and Drug Administration has more about Epidiolex.

Related Stories

First U.S. drug containing marijuana-derived ingredient goes on sale

November 1, 2018
(HealthDay)—The first Food and Drug Administration-approved drug containing an ingredient derived from the marijuana plant went on sale Thursday in the United States.

FDA approves epidiolex for severe forms of epilepsy

June 28, 2018
(HealthDay)—The U.S. Food and Drug Administration has approved Epidiolex (cannabidiol) oral solution for treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome for patients age 2 years and older.

Compound derived from marijuana may benefit children with epilepsy

November 7, 2018
In recent years, cannabinoids—the active chemicals in medical marijuana— have been increasingly touted as a potential treatment for a range of neurological and psychiatric disorders. In a Developmental Medicine & Child ...

Cannabidiol significantly reduces seizures in patients with severe form of epilepsy

May 17, 2018
Cannabidiol (CBD), a compound derived from the cannabis plant that does not produce a "high" and has been an increasing focus of medical research, was shown in a new large-scale, randomized, controlled trial to significantly ...

A sea change in CBD drug policy?

October 2, 2018
The U.S. Drug Enforcement Administration announced a shift Friday that clears the way for the first prescription drug derived from the marijuana plant to make its way to market where it will provide treatment for severe forms ...

CBD oil study shows significant improvement in patients with treatment-resistant epilepsy

August 10, 2018
Findings from the landmark study at the University of Alabama at Birmingham on cannabidiol, or CBD oil, provide the published evidence of significant improvements in seizure frequency and other measures of efficacy in patients ...

Recommended for you

Wiring diagram of the brain provides a clearer picture of brain scan data

December 14, 2018
Already affecting more than five million Americans older than 65, Alzheimer's disease is on the rise and expected to impact more than 13 million people by 2050. Over the last three decades, researchers have relied on neuroimaging—brain ...

Scientists identify method to study resilience to pain

December 14, 2018
Scientists at the Yale School of Medicine and Veterans Affairs Connecticut Healthcare System have successfully demonstrated that it is possible to pinpoint genes that contribute to inter-individual differences in pain.

Parents' brain activity 'echoes' their infant's brain activity when they play together

December 13, 2018
When infants are playing with objects, their early attempts to pay attention to things are accompanied by bursts of high-frequency activity in their brain. But what happens when parents play together with them? New research, ...

In the developing brain, scientists find roots of neuropsychiatric diseases

December 13, 2018
The most comprehensive genomic analysis of the human brain ever undertaken has revealed new insights into the changes it undergoes through development, how it varies among individuals, and the roots of neuropsychiatric illnesses ...

Researchers discover abundant source for neuronal cells

December 13, 2018
USC researchers seeking a way to study genetic activity associated with psychiatric disorders have discovered an abundant source of human cells—the nose.

Researchers find the cause of and cure for brain injury associated with gut condition

December 13, 2018
Using a mouse model of necrotizing enterocolitis (NEC)—a potentially fatal condition that causes a premature infant's gut to suddenly die—researchers at Johns Hopkins say they have uncovered the molecular causes of the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.